Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...
About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...
Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...
Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...
Please provide your email address to receive an email when new articles are posted on . Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study. This is an ASCO Meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback